1. Home
  2. LXFR vs AUTL Comparison

LXFR vs AUTL Comparison

Compare LXFR & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Luxfer Holdings PLC

LXFR

Luxfer Holdings PLC

HOLD

Current Price

$17.11

Market Cap

460.7M

Sector

Industrials

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.49

Market Cap

428.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXFR
AUTL
Founded
1898
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
460.7M
428.5M
IPO Year
2002
2025

Fundamental Metrics

Financial Performance
Metric
LXFR
AUTL
Price
$17.11
$1.49
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
145.0K
1.0M
Earning Date
04-28-2026
05-14-2026
Dividend Yield
3.65%
N/A
EPS Growth
N/A
N/A
EPS
0.13
N/A
Revenue
$384,600,000.00
$10,120,000.00
Revenue This Year
N/A
$80.32
Revenue Next Year
$5.01
$53.96
P/E Ratio
$131.23
N/A
Revenue Growth
N/A
496.00
52 Week Low
$11.19
$1.18
52 Week High
$19.45
$2.70

Technical Indicators

Market Signals
Indicator
LXFR
AUTL
Relative Strength Index (RSI) 46.14 42.06
Support Level $16.68 $1.38
Resistance Level $19.45 $1.52
Average True Range (ATR) 0.63 0.10
MACD -0.24 -0.00
Stochastic Oscillator 23.86 3.77

Price Performance

Historical Comparison
LXFR
AUTL

About LXFR Luxfer Holdings PLC

Luxfer Holdings PLC is engaged in materials engineering and the manufacture of materials, components, and gas containment products. The company has two reportable segments: Elektron and Gas Cylinders. The Elektron segment produces specialty materials based on magnesium and zirconium for applications in aerospace, defense, automotive, and industrial markets. The Gas Cylinders segment manufactures high-pressure gas containment products using aluminum alloys and carbon composite technologies for use in healthcare, emergency response, aerospace, and alternative fuel transportation markets.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: